Status:
COMPLETED
Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The Asian-Pacific Consensus Report has recommended that proton pump inhibitor (PPI)-clarithromycin-amoxicillin or metronidazole treatment for 7 to14 days is the first choice treatment for H pylori inf...
Detailed Description
The Asian-Pacific Consensus Report has recommended that proton pump inhibitor (PPI)-clarithromycin-amoxicillin or metronidazole treatment for 7 to14 days is the first choice treatment for H pylori inf...
Eligibility Criteria
Inclusion
- 1\. H. pylori-infected outpatients with endoscopically proven peptic ulcer diseases or gastritis.
Exclusion
- Previous H. pylori-eradication therapy
- ingestion of antibiotics, bismuth, or PPIs within the prior 4 weeks
- patients with allergic history to the medications used
- patients with previous gastric surgery
- the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)
- pregnant women.
Key Trial Info
Start Date :
March 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2018
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT03383003
Start Date
March 1 2016
End Date
May 1 2018
Last Update
January 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wei-Chen Tai
Kaohsiung City, Taiwan, 833